Publication:
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration

Simple item page
dc.contributor.authorAguareles, José
dc.contributor.authorParaíso-Luna, Juan
dc.contributor.authorPalomares, Belén
dc.contributor.authorBajo-Grañeras, Raquel
dc.contributor.authorNavarrete, Carmen
dc.contributor.authorRuiz-Calvo, Andrea
dc.contributor.authorGarcía-Rincón, Daniel
dc.contributor.authorGarcía-Taboada, Elena
dc.contributor.authorGuzmán, Manuel
dc.contributor.authorMuñoz, Eduardo
dc.contributor.authorGalve-Roperh, Ismael
dc.contributor.authoraffiliation[Aguareles,J; Paraíso-Luna,J; Bajo-Grañeras,R; Ruiz-Calvo,A; García-Rincón,D; García-Taboada,E; Guzmán,M; Galve-Roperh,I] Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. [Aguareles,J; Paraíso-Luna,J; Bajo-Grañeras,R; Ruiz-Calvo,A; García-Rincón,D; García-Taboada,E; Guzmán,M; Galve-Roperh,I] Departamento de Bioquímica y Biología Molecular and Instituto Universitario de Investigación Neuroquímica, Universidad Complutense, Madrid, Spain. [Aguareles,J; Paraíso-Luna,J; Bajo-Grañeras,R; Ruiz-Calvo,A; García-Rincón,D; García-Taboada,E; Guzmán,M; Galve-Roperh,I] Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. [Palomares,B; Muñoz,E] Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain. [Palomares,B; Muñoz,E] Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain. [Palomares,B; Muñoz,E] Hospital Universitario Reina Sofía, Córdoba, Spain. [Navarrete,C] Emerald Health Pharmaceuticals, San Diego, USA.
dc.contributor.funderThis work was supported by the MINECO grant RTC-2015-3364 to EM and IGR cofounded by the European Development Regional Fund in the Framework of the Operative Program “Reinforcement of research, technological development and innovation”. IGR was also supported by grant PI15–00310 and PI18–00941 cofinanced by the European Development Regional Fund “A way to achieve Europe” and EM by the MINECO grant SAF2017–87701-R. JA and JPL were supported by FPI and FPU program fellowship (Ministerio de Educación, Cultura y Deporte) and DGR by Fundación Tatiana de Guzmán el Bueno. BP is a predoctoral fellow supported by the i-PFIS program, Instituto de Salud Carlos III (IFI15/00022; European Social Fund “Investing in your future”).
dc.date.accessioned2020-07-24T09:59:59Z
dc.date.available2020-07-24T09:59:59Z
dc.date.issued2019-03-08
dc.description.abstractThe administration of certain cannabinoids provides neuroprotection in models of neurodegenerative diseases by acting through various cellular and molecular mechanisms. Many cannabinoid actions in the nervous system are mediated by CB1 receptors, which can elicit psychotropic effects, but other targets devoid of psychotropic activity, including CB2 and nuclear PPARγ receptors, can also be the target of specific cannabinoids.es_ES
dc.description.versionYeses_ES
dc.identifier.citationAguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, et al. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. Transl Neurodegener. 2019 Mar 8;8:9.es_ES
dc.identifier.doi10.1186/s40035-019-0148-xes_ES
dc.identifier.essn2047-9158
dc.identifier.pmcPMC6407204
dc.identifier.pmid30899454es_ES
dc.identifier.urihttp://hdl.handle.net/10668/3148
dc.journal.titleTranslational Neurodegeneration
dc.language.isoen
dc.page.number15 p.
dc.publisherBioMed Central Ltd.es_ES
dc.relation.publisherversionhttps://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-019-0148-xes_ES
dc.rights.accessRightsopen access
dc.subjectCannabinoides_ES
dc.subjectHuntingtines_ES
dc.subjectNeurodegenerationes_ES
dc.subjectNeurogenesises_ES
dc.subjectPPARes_ES
dc.subjectCannabinoideses_ES
dc.subjectProteína huntingtinaes_ES
dc.subjectEnfermedades neurodegenerativases_ES
dc.subjectNeurodegenerative diseaseses_ES
dc.subjectNeurogénesises_ES
dc.subjectPeroxisome proliferator-activated receptorses_ES
dc.subjectReceptores activados del proliferador del peroxisomaes_ES
dc.subject.meshMedical Subject Headings::Diseases::Nervous System Diseases::Neurodegenerative Diseaseses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Terpenes::Cannabinoidses_ES
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Differentiation::Neurogenesises_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Receptors, Cytoplasmic and Nuclear::Peroxisome Proliferator-Activated Receptorses_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.titleOral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegenerationes_ES
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Aguareles_OralAdministrationOfThe.pdf
Size:
9.23 MB
Format:
Adobe Portable Document Format
Description:
Artículo publicado
Download

Collections

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía